The detection of Minimal Residual Disease (MRD) in Acute Myeloid Leukemia (AML) can present a challenge because it can require detecting just several malignant cells within thousands – if not millions – of normal cells. One of the major challenges associated with the development and validation of assays for MRD in AML is the absence of cell-based reference materials that feature diverse mutations that may be encountered clinically.
In this scientific poster, SeraCare's scientific experts begin to address the need for standards by developing a full process cell-based reference materials.
To download, fill out the form and you will receive an email with the content.
![AACR 2023 SP - Reference Materials for the Development of Assays for the Detection of Mesurable Residual Disease in Acute Myeloid Leukemia AACR 2023 SP - Reference Materials for the Development of Assays for the Detection of Mesurable Residual Disease in Acute Myeloid Leukemia](https://digital.seracare.com/hs-fs/hubfs/AACR%202023%20SP%20-%20Reference%20Materials%20for%20the%20Development%20of%20Assays%20for%20the%20Detection%20of%20Mesurable%20Residual%20Disease%20in%20Acute%20Myeloid%20Leukemia.png?width=350&height=197&name=AACR%202023%20SP%20-%20Reference%20Materials%20for%20the%20Development%20of%20Assays%20for%20the%20Detection%20of%20Mesurable%20Residual%20Disease%20in%20Acute%20Myeloid%20Leukemia.png)